Format

Send to:

Choose Destination
See comment in PubMed Commons below
Wien Klin Wochenschr. 2014 Jan;126(1-2):23-9. doi: 10.1007/s00508-013-0449-5. Epub 2013 Nov 19.

Long-term follow-up after allogeneic stem cell transplantation in patients with myelodysplastic syndromes or secondary acute myeloid leukemia: a single center experience.

Author information

  • 1Department of Internal Medicine I, Bone Marrow Transplantation Unit, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.

Abstract

OBJECTIVE AND METHODS:

We performed a single center analysis of 60 adult patients (33 males and 27 females) with myelodysplastic syndromes (MDS) or secondary acute myeloid leukemia (AML) who underwent allogeneic hematopoietic stem cell transplantation (HCT) at our institution.

RESULTS:

Allogeneic stem cell in patients were transplanted between 1988 and 2010, 28 had an human leukocyte antigen (HLA)-identical sibling donor, 23 had an HLA-identical unrelated donor, and 9 had an 1 allele mismatched donor. The median age at time of HCT was 44 (range: 18-68) years. Conditioning therapy was myeloablative in 36 patients and consisted of a reduced-intensity conditioning (RIC) regimen in 24 patients. Graft-versus-host disease (GvHD) prophylaxis was performed with a combination of methotrexate and cyclosporine A in 36 patients, and cyclosporine A plus mycophenolate mofetil in 24 patients. The 10-year probability of overall survival was 46 %.

CONCLUSION:

In a multivariate analysis, we identified pretransplantation serum ferritin as the only independent adverse prognostic variable predicting survival in our patients.

PMID:
24249320
[PubMed - indexed for MEDLINE]
PMCID:
PMC4003401
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Write to the Help Desk